NEW YORK (GenomeWeb) – Editas Medicine today announced a collaboration with Adverum Biotechnologies on delivery methods of genome-editing treatments for eye diseases.

Menlo Park, California-based Adverum offers adeno-associated viral vectors and experience in ophthalmology.

"Adverum brings a distinctive technology and experience base," Editas CEO Katrine Bosley said in a statement. "This collaboration aligns highly with our broader, multi-faceted delivery strategy."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Sponsored by

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.